IRIS
GIORGIO, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.630
AS - Asia 3.730
EU - Europa 3.429
SA - Sud America 479
AF - Africa 244
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.516
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.501
SG - Singapore 1.221
IT - Italia 1.046
CN - Cina 1.022
VN - Vietnam 635
FI - Finlandia 456
IE - Irlanda 427
DE - Germania 413
BR - Brasile 381
SE - Svezia 345
HK - Hong Kong 236
FR - Francia 164
ZA - Sudafrica 154
IN - India 146
BD - Bangladesh 122
GB - Regno Unito 120
NL - Olanda 94
TR - Turchia 94
UA - Ucraina 78
RU - Federazione Russa 75
CA - Canada 62
BE - Belgio 52
CI - Costa d'Avorio 43
AR - Argentina 41
MX - Messico 39
JP - Giappone 32
ID - Indonesia 31
AT - Austria 28
IQ - Iraq 26
KR - Corea 25
CZ - Repubblica Ceca 21
ES - Italia 21
PK - Pakistan 20
PL - Polonia 20
TH - Thailandia 20
PH - Filippine 19
EC - Ecuador 14
JO - Giordania 13
RO - Romania 12
VE - Venezuela 12
LT - Lituania 11
SA - Arabia Saudita 11
CO - Colombia 9
EG - Egitto 9
MA - Marocco 8
AL - Albania 7
CH - Svizzera 7
HU - Ungheria 7
TN - Tunisia 7
UZ - Uzbekistan 7
CL - Cile 6
JM - Giamaica 6
KE - Kenya 6
KG - Kirghizistan 6
MY - Malesia 6
PY - Paraguay 6
BO - Bolivia 5
ET - Etiopia 5
HN - Honduras 5
LB - Libano 5
TW - Taiwan 5
PA - Panama 4
PE - Perù 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
AZ - Azerbaigian 2
BG - Bulgaria 2
IL - Israele 2
IR - Iran 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
CG - Congo 1
CM - Camerun 1
GA - Gabon 1
GF - Guiana Francese 1
GR - Grecia 1
Totale 13.507
Salva come PNG Salva come JPEG
Città #
Dallas 1.624
Singapore 663
Ashburn 499
Dublin 427
Chandler 393
San Jose 364
Parma 349
Santa Clara 283
Ann Arbor 282
Beijing 230
Hong Kong 217
Ho Chi Minh City 194
Munich 179
Boardman 174
Johannesburg 149
Dearborn 143
Hanoi 143
Los Angeles 107
New York 107
Helsinki 105
Shanghai 96
Jacksonville 87
Nanjing 76
Hefei 75
Izmir 71
Lauterbourg 68
Princeton 60
Bremen 59
Wilmington 55
Bologna 53
Council Bluffs 47
Abidjan 43
Chicago 42
Brussels 41
São Paulo 41
Columbus 37
Milan 37
Buffalo 35
Shenyang 31
Frankfurt am Main 30
London 30
San Mateo 30
Haiphong 29
Moscow 28
Bangalore 27
Guangzhou 27
Turku 27
Kunming 26
Da Nang 23
Toronto 23
Hillsboro 22
Modena 22
Tokyo 22
Brescia 21
Orem 21
Jakarta 20
Vienna 20
Jinan 19
Lubbock 19
Seoul 19
Nanchang 18
Nuremberg 18
Seattle 18
Des Moines 17
Düsseldorf 17
Fremont 17
Hebei 17
Houston 17
Montreal 17
The Dalles 17
Rio de Janeiro 16
Rome 16
Changsha 15
Grafing 15
Mexico City 15
Reggio Emilia 15
Jiaxing 14
Woodbridge 14
Hangzhou 13
Tianjin 13
Belo Horizonte 12
Brooklyn 12
Dalmine 12
Amman 11
Amsterdam 11
Ankara 11
Boston 11
Brno 11
Chennai 11
Denver 11
Münster 11
Naples 11
Piacenza 11
Warsaw 11
Bangkok 10
Bengaluru 10
Biên Hòa 10
Manchester 10
Phoenix 10
Poplar 10
Totale 8.727
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.699
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 300
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 253
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 251
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 251
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 243
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 223
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 219
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 217
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 217
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 217
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 210
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation 209
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 202
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 190
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 186
Multi-Target CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach 185
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 185
Enhanced photosensitizing properties of protein bound curcumin 178
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 177
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 174
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 172
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 168
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 166
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 165
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 165
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 163
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 163
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 163
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 161
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 161
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 161
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 159
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 158
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 156
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 151
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 151
Structure activity relationship of new EphA2 ligands 150
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 150
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 149
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 148
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 148
Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth 147
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 145
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 143
Discovery of natural extracts interfering with EphA2-ephrinA1 system 143
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 142
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 141
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 140
Target-hopping: a useful approach to identify novel Eph receptor antagonists 139
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 136
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 134
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 127
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 127
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 126
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 125
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 123
Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept 120
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 119
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 115
Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. 114
Therapeutic perspectives of Eph–ephrin system modulation 113
Drug discovery: In silico dry data can bypass biological wet data? 108
Su1816–Protection by Ccr6 Blockade in a Murine Model of Crohn’s Disease 105
UNIPR1331: SMALL EPH/EPHRIN ANTAGONIST BENEFICIAL IN INTESTINAL INFLAMMATION BY INTERFERING WITH TYPE-B SIGNALLING 104
Ephrin or not? Six tough questions on Eph targeting 100
Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives 94
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 89
Targeting Eph/ephrin system in cancer therapy 86
Protection by Eph/ephrin antagonists against TNBS-induced colitis: effects of the route of administration 73
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 67
Dual targeting of EphAs and KDR axis hampers VEGF-induced angiogenesis and glioma stem cell replication 60
Target validation of natural compounds: Perillaldehyde case study 21
Ricerca e caratterizzazione di ligandi per efrine chinasi coinvolte nei processi tumorali 2
Totale 13.699
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.220
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.220
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 0 0 28
2021/2022539 24 23 27 108 36 27 45 44 36 40 18 111
2022/20231.650 161 172 77 133 185 175 42 89 505 27 56 28
2023/2024693 44 41 36 35 47 129 67 53 27 47 75 92
2024/20252.333 98 115 132 117 251 243 176 149 296 200 204 352
2025/20266.249 436 714 1.592 426 642 282 484 180 672 408 256 157
Totale 13.699